A, T., Y, W., N, K., H, A., T, S., T, Y., . . . S, T. (2026). Safety and efficacy profile of S-005151 (Redasemtide), in patients with chronic liver diseases: Phase 2 trial. Inflammation and regeneration, 46(1), . https://doi.org/10.1186/s41232-026-00421-9
Chicago Style (17th ed.) CitationA, Tsuchiya, et al. "Safety and Efficacy Profile of S-005151 (Redasemtide), in Patients with Chronic Liver Diseases: Phase 2 Trial." Inflammation and Regeneration 46, no. 1 (2026). https://doi.org/10.1186/s41232-026-00421-9.
MLA (9th ed.) CitationA, Tsuchiya, et al. "Safety and Efficacy Profile of S-005151 (Redasemtide), in Patients with Chronic Liver Diseases: Phase 2 Trial." Inflammation and Regeneration, vol. 46, no. 1, 2026, https://doi.org/10.1186/s41232-026-00421-9.
Warning: These citations may not always be 100% accurate.
